Personalized medicine in psoriasis: Developing a genomic classifier to predict histological response to Alefacept

Mayte Suárez-Fariñas, Kejal R. Shah, Asifa S. Haider, James G. Krueger, Michelle A. Lowes

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Alefacept treatment is highly effective in a select group patients with moderate-to-severe psoriasis, and is an ideal candidate to develop systems to predict who will respond to therapy. A clinical trial of 22 patients with moderate to severe psoriasis treated with alefacept was conducted in 2002-2003, as a mechanism of action study. Patients were classified as responders or non-responders to alefacept based on histological criteria. Results of the original mechanism of action study have been published. Peripheral blood was collected at the start of this clinical trial, and a prior analysis demonstrated that gene expression in PBMCs differed between responders and non-responders, however, the analysis performed could not be used to predict response.Methods: Microarray data from PBMCs of 16 of these patients was analyzed to generate a treatment response classifier. We used a discriminant analysis method that performs sample classification from gene expression data, via "nearest shrunken centroid method". Centroids are the average gene expression for each gene in each class divided by the within-class standard deviation for that gene.Results: A disease response classifier using 23 genes was created to accurately predict response to alefacept (12.3% error rate). While the genes in this classifier should be considered as a group, some of the individual genes are of great interest, for example, cAMP response element modulator (CREM), v-MAF avian musculoaponeurotic fibrosarcoma oncogene family (MAFF), chloride intracellular channel protein 1 (CLIC1, also called NCC27), NLR family, pyrin domain-containing 1 (NLRP1), and CCL5 (chemokine, cc motif, ligand 5, also called regulated upon activation, normally T expressed, and presumably secreted/RANTES).Conclusions: Although this study is small, and based on analysis of existing microarray data, we demonstrate that a treatment response classifier for alefacept can be created using gene expression of PBMCs in psoriasis. This preliminary study may provide a useful tool to predict response of psoriatic patients to alefacept.

Original languageEnglish (US)
Article number1
JournalBMC Dermatology
Volume10
DOIs
StatePublished - Feb 12 2010
Externally publishedYes

Fingerprint

Precision Medicine
Psoriasis
Gene Expression
Chemokine CCL5
Genes
Clinical Trials
Fibrosarcoma
Response Elements
Discriminant Analysis
Therapeutics
Microarray Analysis
Oncogenes
alefacept
Ligands
Proteins

ASJC Scopus subject areas

  • Dermatology

Cite this

Personalized medicine in psoriasis : Developing a genomic classifier to predict histological response to Alefacept. / Suárez-Fariñas, Mayte; Shah, Kejal R.; Haider, Asifa S.; Krueger, James G.; Lowes, Michelle A.

In: BMC Dermatology, Vol. 10, 1, 12.02.2010.

Research output: Contribution to journalArticle

Suárez-Fariñas, Mayte ; Shah, Kejal R. ; Haider, Asifa S. ; Krueger, James G. ; Lowes, Michelle A. / Personalized medicine in psoriasis : Developing a genomic classifier to predict histological response to Alefacept. In: BMC Dermatology. 2010 ; Vol. 10.
@article{c49faed69fb64782b5cf00d8fa270091,
title = "Personalized medicine in psoriasis: Developing a genomic classifier to predict histological response to Alefacept",
abstract = "Background: Alefacept treatment is highly effective in a select group patients with moderate-to-severe psoriasis, and is an ideal candidate to develop systems to predict who will respond to therapy. A clinical trial of 22 patients with moderate to severe psoriasis treated with alefacept was conducted in 2002-2003, as a mechanism of action study. Patients were classified as responders or non-responders to alefacept based on histological criteria. Results of the original mechanism of action study have been published. Peripheral blood was collected at the start of this clinical trial, and a prior analysis demonstrated that gene expression in PBMCs differed between responders and non-responders, however, the analysis performed could not be used to predict response.Methods: Microarray data from PBMCs of 16 of these patients was analyzed to generate a treatment response classifier. We used a discriminant analysis method that performs sample classification from gene expression data, via {"}nearest shrunken centroid method{"}. Centroids are the average gene expression for each gene in each class divided by the within-class standard deviation for that gene.Results: A disease response classifier using 23 genes was created to accurately predict response to alefacept (12.3{\%} error rate). While the genes in this classifier should be considered as a group, some of the individual genes are of great interest, for example, cAMP response element modulator (CREM), v-MAF avian musculoaponeurotic fibrosarcoma oncogene family (MAFF), chloride intracellular channel protein 1 (CLIC1, also called NCC27), NLR family, pyrin domain-containing 1 (NLRP1), and CCL5 (chemokine, cc motif, ligand 5, also called regulated upon activation, normally T expressed, and presumably secreted/RANTES).Conclusions: Although this study is small, and based on analysis of existing microarray data, we demonstrate that a treatment response classifier for alefacept can be created using gene expression of PBMCs in psoriasis. This preliminary study may provide a useful tool to predict response of psoriatic patients to alefacept.",
author = "Mayte Su{\'a}rez-Fari{\~n}as and Shah, {Kejal R.} and Haider, {Asifa S.} and Krueger, {James G.} and Lowes, {Michelle A.}",
year = "2010",
month = "2",
day = "12",
doi = "10.1186/1471-5945-10-1",
language = "English (US)",
volume = "10",
journal = "BMC Dermatology",
issn = "1471-5945",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Personalized medicine in psoriasis

T2 - Developing a genomic classifier to predict histological response to Alefacept

AU - Suárez-Fariñas, Mayte

AU - Shah, Kejal R.

AU - Haider, Asifa S.

AU - Krueger, James G.

AU - Lowes, Michelle A.

PY - 2010/2/12

Y1 - 2010/2/12

N2 - Background: Alefacept treatment is highly effective in a select group patients with moderate-to-severe psoriasis, and is an ideal candidate to develop systems to predict who will respond to therapy. A clinical trial of 22 patients with moderate to severe psoriasis treated with alefacept was conducted in 2002-2003, as a mechanism of action study. Patients were classified as responders or non-responders to alefacept based on histological criteria. Results of the original mechanism of action study have been published. Peripheral blood was collected at the start of this clinical trial, and a prior analysis demonstrated that gene expression in PBMCs differed between responders and non-responders, however, the analysis performed could not be used to predict response.Methods: Microarray data from PBMCs of 16 of these patients was analyzed to generate a treatment response classifier. We used a discriminant analysis method that performs sample classification from gene expression data, via "nearest shrunken centroid method". Centroids are the average gene expression for each gene in each class divided by the within-class standard deviation for that gene.Results: A disease response classifier using 23 genes was created to accurately predict response to alefacept (12.3% error rate). While the genes in this classifier should be considered as a group, some of the individual genes are of great interest, for example, cAMP response element modulator (CREM), v-MAF avian musculoaponeurotic fibrosarcoma oncogene family (MAFF), chloride intracellular channel protein 1 (CLIC1, also called NCC27), NLR family, pyrin domain-containing 1 (NLRP1), and CCL5 (chemokine, cc motif, ligand 5, also called regulated upon activation, normally T expressed, and presumably secreted/RANTES).Conclusions: Although this study is small, and based on analysis of existing microarray data, we demonstrate that a treatment response classifier for alefacept can be created using gene expression of PBMCs in psoriasis. This preliminary study may provide a useful tool to predict response of psoriatic patients to alefacept.

AB - Background: Alefacept treatment is highly effective in a select group patients with moderate-to-severe psoriasis, and is an ideal candidate to develop systems to predict who will respond to therapy. A clinical trial of 22 patients with moderate to severe psoriasis treated with alefacept was conducted in 2002-2003, as a mechanism of action study. Patients were classified as responders or non-responders to alefacept based on histological criteria. Results of the original mechanism of action study have been published. Peripheral blood was collected at the start of this clinical trial, and a prior analysis demonstrated that gene expression in PBMCs differed between responders and non-responders, however, the analysis performed could not be used to predict response.Methods: Microarray data from PBMCs of 16 of these patients was analyzed to generate a treatment response classifier. We used a discriminant analysis method that performs sample classification from gene expression data, via "nearest shrunken centroid method". Centroids are the average gene expression for each gene in each class divided by the within-class standard deviation for that gene.Results: A disease response classifier using 23 genes was created to accurately predict response to alefacept (12.3% error rate). While the genes in this classifier should be considered as a group, some of the individual genes are of great interest, for example, cAMP response element modulator (CREM), v-MAF avian musculoaponeurotic fibrosarcoma oncogene family (MAFF), chloride intracellular channel protein 1 (CLIC1, also called NCC27), NLR family, pyrin domain-containing 1 (NLRP1), and CCL5 (chemokine, cc motif, ligand 5, also called regulated upon activation, normally T expressed, and presumably secreted/RANTES).Conclusions: Although this study is small, and based on analysis of existing microarray data, we demonstrate that a treatment response classifier for alefacept can be created using gene expression of PBMCs in psoriasis. This preliminary study may provide a useful tool to predict response of psoriatic patients to alefacept.

UR - http://www.scopus.com/inward/record.url?scp=77949436490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949436490&partnerID=8YFLogxK

U2 - 10.1186/1471-5945-10-1

DO - 10.1186/1471-5945-10-1

M3 - Article

C2 - 20152045

AN - SCOPUS:77949436490

VL - 10

JO - BMC Dermatology

JF - BMC Dermatology

SN - 1471-5945

M1 - 1

ER -